Related references
Note: Only part of the references are listed.Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris
John Bowes et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy
K. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
Tobacco smoke is related to Th17 generation with clinical implications for psoriasis patients
Kan Torii et al.
EXPERIMENTAL DERMATOLOGY (2011)
Integrative Responses to IL-17 and TNF-α in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis
Andrea Chiricozzi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
Personalized Medicine in Psoriasis: Concept and Applications
Ibrahim A. Al-Hoqail
Current Vascular Pharmacology (2010)
How genetic variation affects patient response and outcome to therapy for psoriasis
Richard T. Woolf et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2010)
Assessment of the Psoriatic Transcriptome in a Large Sample: Additional Regulated Genes and Comparisons with In Vitro Models
Johann E. Gudjonsson et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population
Kim A. Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2010)
Comparing biological therapies in psoriasis: implications for clinical practice
C. E. M. Griffiths
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2010)
Evaluation of the Psoriasis Transcriptome across Different Studies by Gene Set Enrichment Analysis (GSEA)
Mayte Suarez-Farinas et al.
PLOS ONE (2010)
Transcriptional Profiles of Leukocyte Populations Provide a Tool for Interpreting Gene Expression Patterns Associated with High Fat Diet in Mice
William R. Swindell et al.
PLOS ONE (2010)
Plato's Cave Algorithm: Inferring Functional Signaling Networks from Early Gene Expression Shadows
Yishai Shimoni et al.
PLOS COMPUTATIONAL BIOLOGY (2010)
Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept
Mayte Suarez-Farinas et al.
BMC DERMATOLOGY (2010)
Paradoxical adverse effects of anti-TNF-α treatment: onset or exacerbation of cutaneous disorders
Manuelle Viguier et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2009)
Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis
Yaowei Zhu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
How to individualize treatments?
Peter C. M. van de Kerkhof
JOURNAL OF DERMATOLOGICAL TREATMENT (2009)
Association between IL13 Polymorphisms and Psoriatic Arthritis Is Modified by Smoking
Kristina Callis Duffin et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Global Gene Expression Analysis Reveals Evidence for Decreased Lipid Biosynthesis and Increased Innate Immunity in Uninvolved Psoriatic Skin
Johann E. Gudjonsson et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis
Antonella Di Cesare et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
Rajan P. Nair et al.
NATURE GENETICS (2009)
Mechanisms of Disease: Psoriasis.
Frank O. Nestle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Onset or exacerbation of cutaneous psoriasis during TNFα antagonist therapy
Daniel Wendling et al.
JOINT BONE SPINE (2008)
Cellular genomic maps help dissect pathology in human skin disease
Asifa S. Haider et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Type I Interferon: Potential Therapeutic Target for Psoriasis?
Yihong Yao et al.
PLOS ONE (2008)
Pathogenesis and therapy of psoriasis
Michelle A. Lowes et al.
NATURE (2007)
Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis
B. Elewski et al.
BRITISH JOURNAL OF DERMATOLOGY (2007)
Clinical pharmacokinetics and use of infliximab
Ulrich Klotz et al.
CLINICAL PHARMACOKINETICS (2007)
An overview of the pharmacokinetics and pharmacodynamics of efalizumab: A monoclonal antibody approved for use in psoriasis
A Joshi et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Gene expression profiling of Japanese psoriatic skin reveals an increased activity in molecular stress and immune response signals
JK Kulski et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2005)
Identification of differentially expressed genes in psoriasis using expression profiling approaches
K Itoh et al.
EXPERIMENTAL DERMATOLOGY (2005)
Multivariate outlier detection in exploration geochemistry
P Filzmoser et al.
COMPUTERS & GEOSCIENCES (2005)
Immunopathogenic mechanisms in psoriasis
JE Gudjonsson et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2004)
Up-regulation of interleukin-13 receptor α1 on human keratinocytes in the skin of psoriasis and atopic dermatitis
J Wongpiyabovorn et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2003)
Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array
XH Zhou et al.
PHYSIOLOGICAL GENOMICS (2003)
Summaries of affymetrix GeneChip probe level data
RA Irizarry et al.
NUCLEIC ACIDS RESEARCH (2003)
NetAffx: Affymetrix probesets and annotations
GY Liu et al.
NUCLEIC ACIDS RESEARCH (2003)
Interleukin-13 receptor in psoriatic keratinocytes:: Overexpression of the mRNA and underexpression of the protein
JC Cancino-Díaz et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2002)
Interleukin 13 in synovial fluid and serum of patients with psoriatic arthritis
A Spadaro et al.
ANNALS OF THE RHEUMATIC DISEASES (2002)
Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies
AM Bowcock et al.
HUMAN MOLECULAR GENETICS (2001)
Share Paper
